Chemical Composition of Urine and Mechanisms of Crystal Formation in Urolithiasis
PDF

How to Cite

Nozima , A., Anvarova , C., & Davronova , S. (2026). Chemical Composition of Urine and Mechanisms of Crystal Formation in Urolithiasis. Sog‘liqni Saqlashda Yangi Yondashuvlar, 1(2), 25-34. https://doi.org/10.5281/zenodo.20057062

Abstract

The physicochemical and metabolic properties of urine play a decisive role in the pathogenesis of urolithiasis, involving a multistage cascade process. By its nature, urine is considered a metastable solution, and crystal formation depends not only on the amount of salts but also directly on the concentration of ions, the pH level of the environment, and the dynamic balance between inhibitory and promotive substances.

This study provides an in-depth analysis of the fundamental stages involved in the formation of urolithiasis, including supersaturation, nucleation, crystal growth, aggregation, and retention processes. In addition, the effectiveness of modern diagnostic methods and the principles of minimally invasive treatment are examined from the perspective of biochemical balance. This analysis serves as a theoretical basis for metaphylaxis and the development of individualized treatment strategies for the disease.

PDF

References

1. Bargagli M, et al. Kidney stone disease: pathophysiology and management. Nature Reviews Nephrology. 2025.

2. Allam EAH. Urolithiasis: pathophysiology and mechanisms. African Journal of Urology. 2024.

3. Sakhaee K. Kidney stones: pathogenesis and management. Endocrine Reviews. 2012. Dardamanis M. Pathomechanisms of nephrolithiasis. Hippokratia. 2013.

4. Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006;367(9507):333–344.https://doi.org/10.1016/S0140-6736(06)68071-9⁠

5. Curhan GC. Epidemiology of stone disease. Urol Clin North Am. 2007;34(3):287–293.

6. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest. 2005;115(10):2598–2608.

7. Khan SR. Calcium oxalate crystal interaction with renal tubular epithelium. Urol Res. 2006;34:398–401.

8. Robertson WG. Understanding the pathogenesis of kidney stones. Ann Clin Biochem. 2004;41:77–84.

9. Lieske JC. Role of urinary inhibitors of crystallization. Curr Opin Nephrol Hypertens. 2014;23(4):359–364.

10. Trinchieri A. Epidemiology of urolithiasis. Arch Ital Urol Androl. 2008;80(1):1–4.

11. Parmar MS. Kidney stones: pathophysiology and medical management. Can Med Assoc J. 2001;164(10):1493–1500.

12. Pak CY. Medical management of urinary stone disease. Nephron Physiol. 2004;98:49–53.

13. Worcester EM, Coe FL. Clinical practice: calcium kidney stones. N Engl J Med. 2010;363:954–963.